INTI · Inhibitor Therapeutics, Inc.

In Q1 FY2026, Inhibitor Therapeutics, Inc. (INTI) reported operating income of -$695.6K, a 3.1% widening from -$674.6K in the year-ago quarter. This deterioration reflects heightened research and development expenses, with the increase quarter-over-quarter primarily resulting from fees associated with services provided by Frameshift during the period, as detailed in Item 2 - Management's Discussion and Analysis. Management notes that such expenses consist primarily of internal personnel costs—including salaries, benefits, and related costs—as well as payments to third parties supporting R&D activities. These dynamics underscore the company's focus on advancing its pipeline, even as they contribute to broader loss expansion.

Net income stood at -$686.4K for the quarter, marking an 8.5% deeper loss compared to -$632.8K in Q1 FY2025. Diluted EPS remained flat at $0.00 year-over-year. The persistent operating deficits highlight the challenges of a clinical-stage biopharma with limited revenue generation, where R&D investments drive the financial profile. Net cash provided by operating activities showed improvement, reaching -$1.1M versus -$1.3M prior year, which management attributes to tighter working capital management amid ongoing operational demands.

Liquidity remains a critical concern, as management discloses in Item 2 that given projected operating requirements and existing cash equivalents, the company anticipates insufficient funds to sustain operations through one year following the financial statement issuance date—before considering management's plans to address these conditions. This projection is based on historical experience, external expert advice, and other assumptions deemed reasonable by leadership. Notably, the company expects R&D expenses to continue increasing in the future, contingent on results from upcoming FDA meetings, which could further pressure cash flows.

Management has referenced potential proceeds from an offering intended for working capital and general corporate purposes, though receipt remains uncertain. As a result, plans do not currently alleviate substantial doubt about the company's ability to continue as a going concern. Investors should monitor FDA interactions and capital-raising efforts closely, as these will dictate the trajectory of expense growth and liquidity stabilization. The Frameshift engagement exemplifies how targeted consulting supports R&D progress but amplifies near-term financial strain in this capital-intensive sector.